Abstract:Although antiretroviral therapy (ART) is undeniably effective at blocking HIV replication to levels below the detection limit of conventionally available assays [1,2] , neither early [3] nor prolonged treatment is sufficient to cure HIV infection [4–6] . Indeed, upon treatment interruption, plasma viral rebound occurs in majority of HIV-infected individuals within a relatively short time frame, around 14–21 days [7,8] , demonstrating that HIV persists despite ART. Historically, the quantification of HIV-infected cells relied mainly on either PCR-based methods measuring viral nucleic acids [9–11] and/or on viral outgrowth assays assessing viral competency [12,13] . These assessments supported the paradigm that viral persistence was primarily associated with quiescent yet inducible HIV infection of long-lived resting memory CD4 + T cells in the blood, referred to as the 'latent reservoir' [4,5,14] which was largely unchanging and stable over-time [6,15] . In contrast to peripheral blood, secondary lymphoid organs (such as the spleen, lymph nodes, and gut-associated lymphoid tissues), where viral replication predominantly occurs, remained less extensively investigated [16,17] . This was mainly attributed to two major reasons: limited accessibility to tissue samples from individuals on ART due to ethical considerations, and tissues were believed to harbor HIV-infected cells actively expressing HIV genes and viral transcripts, constituting an 'active reservoir' susceptible to elimination – either directly through viral cytopathic effects or through cell-mediated immunity [18] . However, recent studies have played a pivotal role in unravelling the complexity of the HIV reservoir in terms of its cellular composition, tissue distribution, and transcriptional activity [19] .

Targeting HIV persistence in the tissue

Research progress on HIV latency-reversing agents and its mechanism

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

Eliminating the HIV tissue reservoir: current strategies and challenges

HIV Persistence, Latency, and Cure Approaches: Where Are We Now?

Targeting Viral Transcription for HIV Cure Strategies

Persistent HIV-1 transcription during ART: time to reassess its significance?

Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure

Translational eradication approaches

The multifaceted nature of HIV tissue reservoirs

HIV Tissue Reservoirs: Current Advances in Research

The reservoir of latent HIV

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection

Current approaches to assess HIV-1 persistence

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs

HIV Pol: does it offer therapeutic targets for HIV?

Treatment of Human Immunodeficiency Virus-1: Current Challenges and Future Perspectives

HIV Expression in Infected T Cell Clones

Research progress on human immunodeficiency virus reservoir and its eradication

Strategies to target the central nervous system HIV reservoir

Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART